18 January 2022
Paula Chan, Senior Portfolio Manager, Asia Fixed Income
Isaac Meng, Portfolio Manager, Asia Fixed Income
As global inflation trends higher, investors would like to look for potential hedges against the erosion of real returns. In this investment note, Paula Chan (Senior Portfolio Manager, Asia Fixed Income) and Isaac Meng (Portfolio Manager, Asia Fixed Income) outline their key observations and explain why they think China government bonds and the Chinese renminbi (CNY) have the potential to act as hedges against US inflation.
According to conventional wisdom, there is a belief that US inflationary pressures can be negative for the Chinese yuan (CNY). This is because, historically, US inflationary pressures have led the Federal Reserve to tighten monetary policy, and US Treasury yields then to move higher as investors became concerned about inflation. Consequently, the yield advantage of China’s interest rates over US Treasury yields would narrow, as the latter rises while the former remains stable. The yield advantage of China bonds has been one of the key drivers for global investors to invest in China bonds, which has helped the CNY to appreciate. Therefore, if the yield differential declines, investors could pull funds away from China bonds leading to a weaker CNY against the US dollar.
Contrary to the above expectations, we have noticed that US inflationary pressures did not necessarily lead to an underperformance in the CNY. In fact, the two charts below show that the CNY had tracked US inflationary pressures quite closely, as indicated by US 5-Year breakeven rates, which is a gauge of the market’s expectations for US inflation (Chart 1). Meanwhile, the CNY had also tracked the official annual US CPI rate on an ex-post basis (Chart 2). Both charts tell us that as US inflation ticked higher, the CNY appreciated against the US dollar during these periods.
Chart 1: CNY appreciated against USD as US inflationary expectation (US 5-year break-even rates) moved higher
Bloomberg, data as of 30 November 2021.
Chart 2: CNY appreciated against USD as US inflationary (official annual CPI) moved higher
Bloomberg, data as of 31 October 2021.
Thinking this through, we believe it could make sense for China onshore bonds (and the CNY) to be a positive-yielding hedge against inflationary pressures due to the following reasons:
In response to the global pandemic, the US Federal Reserve has been dovish and is still expanding its balance sheet well into the first quarter of 2022 despite tapering. Even with the market pricing in +0.75% in rate hikes for 2022, negative US real rates will prevail with CPI running above 5%.
We believe higher US inflation may not be transitory in nature that only reflects temporary supply shocks. Rather, higher inflation is likely a consequence of stronger US demand and goods consumption. Higher consumption and imports in the US are positive contributors to China’s trade surplus which is positive for the CNY.
With US inflation currently outpacing China inflation, the value of the CNY (in real terms) is likely to be closer to fair value compared with the US dollar. The latter is more likely to be overvalued due to its higher inflation based on the real effective exchange rate (REER). The REER is a measure of a currency’s value against those of its major trading partners after adjusting for inflation.
A market environment with higher breakeven rates and low-to-negative real yields is generally associated with a “risk-on” mode, i.e., global investors are more likely to allocate away from US Treasuries to higher-risk asset classes in this environment. Hence, on this basis, a greater allocation to CNY assets can be expected.
As inflation has ramped up in the last 12 months, we have seen US Treasury inflation-linked bonds outperform US Treasuries over this time. Similarly, China bonds (unhedged) have performed strongly and kept pace with the performance of US Treasury Inflation-linked bonds over the same period, giving support to our thesis that China bonds can provide investors with a hedge against US inflation.
Chart 3: 5-year returns of China bonds (unhedged) vs. US Treasury inflation-linked bonds
Bloomberg, data as of 30 November 2021.
We have highlighted some of our key observations and explained why we think China government bonds and the CNY Chinese renminbi have the potential to act as hedges against US inflation. China bonds are already an attractive asset class, given their higher nominal and real yields and diversification benefits due to a lower correlation with other assets. However, the potential for China bonds to be a positive-yielding asset that also hedges against rising global inflation further enhances their appeal. We believe there is now an even stronger case for considering China bonds as a key part of global investors’ portfolios.
China rolls out measures to support economic growth
We believe that the latest supportive measures reiterate China’s stance on economic stability and see opportunities in China and Hong Kong equities that could benefit from these policy actions.
Sri Lanka’s difficult road ahead
Sri Lanka's imminent default holds lessons for investors and underscores the value of a sustainable investing framework.
Monetary tightening amid heightened uncertainty: implications for emerging markets
The March FOMC meeting told us that the Fed is still prepared to proceed with rate hikes to fight near-term inflation. Do we need to worry about another Fed tantrum in emerging markets? From a macro perspective, there are two ways to answer this question.
The information provided on this website is for informational purposes only and is intended solely for use by Singapore residents and is not intended for distribution to, or use by, any person or entity in the United States, or any jurisdiction or country where such distribution or use would be contrary to law or regulation, or which would subject Manulife Investment Management (Singapore) Pte. Ltd. (Company Registration No. 200709952G) and/or its affiliates (collectively hereafter "Manulife") or any of Manulife's products or services to any registration requirement within such jurisdiction or country. Nothing on this website shall be construed as financial advice or an offer, invitation, solicitation or recommendation by or on behalf of Manulife to any person to buy or sell any Fund and is no indication of trading intent in any Fund managed by Manulife. None of the information or analyses presented are intended to form the basis for any investment decision, and no specific recommendations are intended.
Investments in any Fund are not deposits in, guaranteed or insured by Manulife and involve risks. The value of units in any Fund and any income accruing to it may fall or rise. Past performance of the Fund is not necessarily indicative of future performance. The Fund may use or invest in financial derivative instruments. Investors should read the prospectus and seek advice from a financial adviser, before deciding whether to subscribe for or purchase units in any Fund. In the event an investor chooses not to seek advice from a financial adviser, he should consider whether the Fund(s) is/are suitable for him. Copies of the prospectus and the product highlights sheets can be obtained from Manulife or its distributors, for further details (including the risk factors) and charges.
The Manager shall have the absolute discretion to determine whether a distribution is to be made in respect of any Fund as well as the rate and frequency of distributions to be made. The intention of the Manager to make the distribution and the distribution yield for the Fund is not guaranteed, and the Manager may review the distribution policy depending on prevailing market conditions. Distributions may be made out of income, net capital gains and/or capital. Past distribution yields and payments are not necessarily indicative of future distribution yields and payments. Any payment of distributions by the Fund may result in an immediate decrease in the net asset value per unit.
All advertisements or publications provided on this website have not been reviewed by the Monetary Authority of Singapore.
Manulife Investment Management (Singapore) Pte. Ltd. (Company Registration No. 200709952G)